Editor’s note: The Parkinson’s News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. The investigational medication SEP-363856 might ease symptoms of Parkinson’s disease psychosis, according to data from a…
Dopamine-releasing cells in the brain, much like most other hormone-producing cells, have a self-regulating feedback mechanism that controls their activity, researchers have discovered. That is, healthy nerve cells themselves determine how much dopamine will be released, the research team found, in contrast with the prevailing view that nearby cells “control”…
A new research project aims to determine whether medications developed to treat depression might be viable candidates for easing some troubling side effects of treatments for Parkinson’s disease, including levodopa. Parkinson’s is caused by the death or dysfunction of cells in the brain that make a neurotransmitter (brain signaling…
Regular dental visits and routine tooth brushing with alternating hands are among recommendations for better oral health in people with Parkinson’s disease, researchers report. Tooth decay and receding gums are known problems for these patients, and often overlooked due to the nature of this neurodegenerative disorder, the team noted. The paper,…
Dopamine-producing neurons in the brain grow throughout life, but this growth is hindered by a genetic mutation that is associated with the development of Parkinson’s disease, a new study demonstrates. The researchers hope these findings will lead scientists to “focus on enhancing the generation of new dopamine-producing neurons, rather…
In Parkinson’s disease, iron accumulates in certain parts of the brain that have characteristic genetic profiles, according to a new study. This finding may help to explain the biological processes that cause Parkinson’s, which could be important for developing treatments. The study, “Regional brain iron…
The Parkinson’s Foundation has announced that this year’s Moving Day walk season will include virtual and contactless events. Moving Day, which is the Foundation’s signature fundraising event, aims to increase awareness about Parkinson’s disease, as well as raise money that will fund research and provide expert care for…
ANVS401, an investigational therapy for neurodegenerative diseases being developed by Annovis Bio, improved the speed and coordination of people with Parkinson’s disease in a Phase 2a clinical trial, an interim analysis suggests. “The results from this interim analysis are very encouraging. This brings us one step closer to…
Newron Pharmaceuticals and Zambon Pharma agreed to jointly support a potentially pivotal clinical trial of Xadago (safinamide) as a treatment of levodopa-induced dyskinesia in people with Parkinson’s disease. Under the terms of the agreement, Newron and Zambon will evenly share the cost of the intended study. Newron, which developed…
People with Parkinson’s disease have substantial changes in the bacteria living in their gut relative to people without this neurodegenerative disorder, an analysis underscores. “This dysbiosis [microbial imbalance] might result in a pro-inflammatory status which could be linked to the recurrent gastrointestinal symptoms affecting PD [Parkinson’s disease] patients,” its…
Get regular updates to your inbox.